Device Trial Radar · NCT07347379
Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study
Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
108
Actual
Start
Nov 13, 2025
Primary completion
Aug 17, 2026
Study completion Sep 9, 2026
Sponsor
- Lead sponsor
- RxSight, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 16, 2026
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an observational, follow up study of subjects previously enrolled in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study". The primary objective of this study is to collect long-term safety and effectiveness data on RxSight LAL in subjects previously implanted in the "RxSight Light Adjustable Lens (LAL) and Light Delivery Device (LDD) New Enrollment Study".
Conditions
- Aphakia Cataract
Interventions
Light Adjustable lens (LAL) and Light Delivery Device (LDD)Device
Experimental treatment group received Light adjustable lens with Light delivery Device treatments
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean absolute manifest refraction spherical equivalent (|MRSE|) at the Long-Term follow up visitTime frame: Up to 55 months
- Mean manifest cylinder at the Long-Term follow up visitTime frame: Up to 55 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Vance Thompson Vision
Alexandria, Minnesota
Vance Thompson Vision
Omaha, Nebraska
Key-Whitman Eye Center
Dallas, Texas
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.